Tag Archives: COVID-19 vaccine

Chinese Covid-19 Vaccine Ready For Public By November

Chinese manufacturers have been bullish about development, with companies Sinovac Biotech and Sinopharm even putting their vaccine candidates on display at a trade fair in Beijing this month. A China-developed coronavirus vaccine could be ready for the public as early as November, a Chinese official has told state television, as the global race to clear the final round of trials heats up.

Representatives of the firms told AFP that they hope their vaccines will be approved after phase 3 trials as early as year-end.

And on late Monday, the chief biosafety expert at the Chinese Centre for Disease Control told state broadcaster CCTV that a vaccine would be available to the general public “around November or December.”
https://medicalxpress.com/

Sinovac COVID-19 Vaccine Available To Brazilians In December

The governor of Brazil’s São Paulo State said on Wednesday that Phase 3 clinical trials of a potential COVID-19 vaccine developed by China’s Sinovac Biotech Ltd have shown promising results and it may be available to Brazilians as early as December.
Governor João Dória added that Phase 2 trials of the potential vaccine had shown an immune response of 98% in the elderly. Some 9,000 Brazilians are participating in the Sinovac vaccine trials, which are being conducted by the Butantan Institute in Sao Paulo city, the State capital. Brazil, which has the third worst outbreak of the novel coronavirus in the world after the United States and India, has become a testing ground for at least two vaccine candidates.

Brazil trials of Sinovac COVID-19 vaccine show promising results
One such vaccine is being developed by AstraZeneca, which has had to pause global trials after an unexplained illness in a participant in Britain. At the start of next year, Phase 3 trials of Russia’s “Sputnik-VCOVID-19 vaccine will also be conducted on 10,000 volunteers in Brazil in partnership with the State of Paraná’s Technology Institute, known as Tecpar.

Source: https://timesofindia.indiatimes.com/

Russian COVID-19 vaccine approval imminent

Russia’s first potential COVID-19 vaccine will win local regulatory approval in the first half of August and be administered to frontline health workers soon afterwards, a development source close to the matter told Reuters. A state research facility in Moscow – the Gamaleya Institute – completed early human trials of the adenovirus-based vaccine this month and expects to begin large-scale trials in August.

The vaccine will win regulatory approval from authorities in Russia while that large-scale trial continues, the source said, highlighting Moscow’s determination to be the first country in the world to approve a vaccine. The speed at which Russia is moving to roll out the vaccine has prompted some Western media to question whether Moscow is putting national prestige before solid science and safety.

(Regulatory) approval will be in the first two weeks of August,” the development source said. “August 10 is the expected date, but it will definitely be before August 15. All (trial) results so far are highly positive.”

The source added that Russian health workers treating COVID-19 patients will be offered the chance of volunteering to be vaccinated soon after the vaccine receives the regulatory approval. Separately, Russia’s Interfax news agency cited “an informed source” as saying the vaccine would be registered from Aug. 10-12 and be administered from Aug. 15 onwards.

https://reuters.com/

China’s Phase 2 Trial Finds COVID-19 Vaccine Safe, Inducing Immune Response

A phase 2 trial of a COVID-19 vaccine candidate conducted in China has found that the vaccine is safe and induces an immune response, according to a new study published Monday in medical journal The Lancet.
The results provide data from a wider group of participants than the phase 1 trial, which was published in May. Phase 1 trial involved 108 healthy adults and it demonstrated promising results.

The phase 2 trial adds further evidence on safety and immunogenicity in a large population than the phase 1 trial. This is an important step in evaluating this early-stage experimental vaccine and phase 3 trials are now underway,” said Professor Fengcai Zhu from Jiangsu Provincial Center for Disease Control and Prevention, China.
According to The Lancet, the trial of the Ad5 vectored COVID-19 vaccine candidate was conducted in the central Chinese city of Wuhan with 508 participants taking part. Approximately two thirds of participants were aged 18-44 years, with a quarter aged 45-54 years, and 13 percent aged 55 years or older.
http://www.xinhuanet.com/